


Supplementary Figure S1



Supplementary Figure S1. Representation of tarloxotinib conversion to its irreversible EGFR/HER2 inhibitor. Attachment of a hypoxia trigger to tarloxotinib significantly reduces the potency of the prodrug, allowing for administration at higher relative concentrations than the cognate TKI (tarloxotinib-E).